LGALS3 and familial pancreatic carcinoma: CA19-9 is currently the most widely used biomarker for pancreatic cancer, and integrating it with Gal-3 may enhance diagnostic accuracy and provide complementary information due to their distinct targets in pancreatic cancer6.